Cancer immunotherapies that target the immunosuppressive checkpoint receptors cytotoxic T-lymphocyte-associated protein 4 (CTLA4) or PD-1 and its ligand PD-L1, have changed the landscape of anticancer immunotherapy [4]. This evidence concerns the gene CTLA4 and cancer.